CA Patent

CA2841886C — 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors

Assigned to Merck Sharp and Dohme BV · Expires 2016-08-16 · 10y expired

What this patent protects

There are provided 6-5 membered fused pyridine ring compounds according to formula l (see formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and their possible use in therapy. The disclosure relates to the use of …

USPTO Abstract

There are provided 6-5 membered fused pyridine ring compounds according to formula l (see formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and their possible use in therapy. The disclosure relates to the use of 6-5 membered fused pyridine ring compounds according to formula l for inhibiting Bruton's Tyrosine Kinase (Btk) in vitro which may allow the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2841886C
Jurisdiction
CA
Classification
—
Expires
2016-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.